Department of Antibody Engineering, Genentech Inc., South San Francisco, CA, United States of America.
DevSci BioAnalytical Sciences, Genentech Inc., South San Francisco, CA, United States of America.
PLoS One. 2020 Dec 21;15(12):e0244158. doi: 10.1371/journal.pone.0244158. eCollection 2020.
The proactive generation of anti-idiotypic antibodies (anti-IDs) against therapeutic antibodies with desirable properties is an important step in pre-clinical and clinical assay development supporting their bioanalytical programs. Here, we describe a robust platform to generate anti-IDs using rabbit single B cell sorting-culture and cloning technology by immunizing rabbits with therapeutic drug Fab fragment and sorting complementarity determining regions (CDRs) specific B cells using designed framework control as a negative gate to exclude non-CDRs-specific B cells. The supernatants of cultured B cells were subsequently screened for binding to drug-molecule by enzyme-linked immunosorbent assay and the positive hits of B cell lysates were selected for cloning of their immunoglobulin G (IgG) variable regions. The recombinant monoclonal anti-IDs generated with this method have high affinity and specificity with broad epitope coverage and different types. The recombinant anti-IDs were available for assay development to support pharmacokinetic (PK) and immunogenicity studies within 12 weeks from the start of rabbit immunization. Using this novel rapid and efficient in-house approach we have generated a large panel of anti-IDs against a series of 11 therapeutic antibody drugs and successfully applied them to the clinical assay development.
主动生成针对具有理想特性的治疗性抗体的抗独特型抗体(抗 ID)是支持其生物分析计划的临床前和临床检测开发的重要步骤。在这里,我们描述了一种使用兔单 B 细胞分选培养和克隆技术生成抗 ID 的稳健平台,通过用治疗药物 Fab 片段免疫兔子,并使用设计的框架控制作为阴性门来排除非 CDR 特异性 B 细胞,对特异性 B 细胞进行分选。随后,通过酶联免疫吸附试验筛选培养的 B 细胞上清液中与药物分子的结合情况,并对 B 细胞裂解物的阳性产物进行克隆,以获得其免疫球蛋白 G(IgG)可变区。使用该方法生成的重组单克隆抗 ID 具有高亲和力和特异性,广泛覆盖表位,并具有不同类型。从兔子免疫开始的 12 周内,即可获得这些重组抗 ID,用于支持药代动力学(PK)和免疫原性研究。我们使用这种新颖的快速有效的内部方法,已经针对一系列 11 种治疗性抗体药物生成了大量的抗 ID,并成功地将其应用于临床检测开发。